Madrigal's Rezdiffra improves or stabilizes liver stiffness in up to 93% of patients in real-world studies
MDGL•Madrigal Pharmaceuticals said real-world studies presented at the 2026 AASLD Liver Meeting found liver stiffness improved or remained stable in up to 93% of patients treated with Rezdiffra. The company also reported improvements in liver fat and cardiometabolic markers, with benefits seen regardless of concurrent GLP-1 therapy.
1. Real-world results
Madrigal Pharmaceuticals announced real-world Rezdiffra results presented at the 2026 AASLD Liver Meeting for metabolic dysfunction-associated steatohepatitis. Most patients showed improved or stable liver stiffness roughly one year into treatment.
2. Treatment and safety
The company said benefits were observed regardless of concurrent GLP-1 therapy, and that most patients remained on treatment at one year, with high adherence among those continuing therapy. Safety findings were consistent with clinical trials, and reported treatment-related adverse events were infrequent.
